Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2000
04/13/2000WO2000020039A1 Methods and adjuvants for stimulating mucosal immunity
04/13/2000WO2000020036A1 Pharmaceutical compositions containing paclitaxel
04/13/2000WO2000020035A1 Oxybutynin formulations and methods of use
04/13/2000WO2000020034A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer
04/13/2000WO2000020033A1 Tablets immediately disintegrating in the oral cavity
04/13/2000WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer
04/13/2000WO2000020024A2 Methods for the treatment of non-thyroid disorders
04/13/2000WO2000020023A2 Null igf for the treatment of cancer
04/13/2000WO2000020019A2 A composition for the prevention and/or treatment of atherosclerosis
04/13/2000WO2000020016A1 Animal stereotypy
04/13/2000WO2000020014A1 Plant extracts for the treatment of increased bone resorption
04/13/2000WO2000020010A1 Alternate day administration of copolymer 1 for treating autoimmune diseases
04/13/2000WO2000020009A1 Antibacterial agents and process for producing the same
04/13/2000WO2000020008A1 Use of bisphosphonic acid derivatives for preparing a medicine for treating lameness
04/13/2000WO2000020007A1 Method and compositions for increasing bone mass
04/13/2000WO2000020006A1 Use of diltiazem for treating retinal pathologies
04/13/2000WO2000020005A1 Pharmaceutical compositions containing an opiate analgesic and a synergizing substance
04/13/2000WO2000020003A1 Naphthalenecarboxamides as tachykinin receptor antagonists
04/13/2000WO2000020002A1 Composition for treatment of light-injured retinal degeneration disease
04/13/2000WO2000020001A1 Mglur5 antagonists for the treatment of pain and anxiety
04/13/2000WO2000020000A1 Controlled release oral preparations of esculetin and its derivatives
04/13/2000WO2000019999A1 Fulvic acid and its use in the treatment of various conditions
04/13/2000WO2000019998A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
04/13/2000WO2000019997A1 Controlled release dosage from comprising oxybutynin
04/13/2000WO2000019996A1 Controlled drug release system of retinoic acid
04/13/2000WO2000019995A1 Angiogenesis inhibitor
04/13/2000WO2000019993A2 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
04/13/2000WO2000019992A1 Method for treating insulin resistance through hepatic nitric oxide
04/13/2000WO2000019991A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
04/13/2000WO2000019990A2 Rar antagonists as male anti-fertility agents
04/13/2000WO2000019989A2 Use of catechol derivatives as proteinase inhibitors
04/13/2000WO2000019987A1 Mucosal originated drug delivery systems and animal applications
04/13/2000WO2000019986A1 Tape material for transcutaneous absorption
04/13/2000WO2000019985A2 New sustained release oral formulations
04/13/2000WO2000019984A2 Coated medicament forms with controlled active substance release
04/13/2000WO2000019978A2 Compositions and methods for enhancing receptor-mediated cellular internalization
04/13/2000WO2000019977A1 Composition and method for medicated chewing gum delivery system
04/13/2000WO2000019975A1 Use of testosterone esters and/or testosterone for producing bucally applicable bio-adhesive systems with time-released active ingredients
04/13/2000WO2000019969A1 Hair tonic
04/13/2000WO2000019964A2 Novel compositions and methods for prevention and treatment of protozoal disease
04/13/2000WO2000019883A2 Compositions and methods of disease diagnosis and therapy
04/13/2000WO2000019824A1 Novel treatment for stroke management
04/13/2000WO2000019823A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
04/13/2000WO2000003015A3 Human transport protein homologs
04/13/2000WO2000002877A3 New pharmaceutically active compounds
04/13/2000WO2000002850A3 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators
04/13/2000WO2000002545A3 Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain
04/13/2000WO1999066911A3 Gastro-intestinal adverse effect-free composition comprising an l-carnitine replacement
04/13/2000WO1999065490A3 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
04/13/2000WO1999065462A3 Use of aminosterol derivatives as chloride ionphores
04/13/2000WO1999063978A3 Methods of treating microbial infection and therapeutic formulations therefor
04/13/2000WO1999062451A9 Topical transdermal treatments
04/13/2000WO1999061009A3 PHARMACEUTICAL PREPARATIONS FOR REGULATING THE RELEASE OF INSULIN BY INFLUENCING THE β-CELL OF THE PANCREATIC ISLETS OF LANGERHANS
04/13/2000WO1999059563A3 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
04/13/2000WO1999059562A3 Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
04/13/2000WO1999053897A3 Topical formulation comprising poloxamers and further microbicides, and an applicator
04/13/2000WO1999038500A3 The human calcium-sensing receptor in the detection and treatment of cancer
04/13/2000WO1999029687A8 (benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
04/13/2000DE19845406A1 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Substituted 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino) - propanol derivatives, process for their preparation, pharmaceutical compositions containing them and their use
04/13/2000DE19845403A1 Mit Gallensäuren verknüpfte Porpanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung With bile acids linked Porpanolaminderivate, processes for their preparation, pharmaceutical compositions containing them and their use
04/13/2000DE19845402A1 Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung -Containing heterocycles substituted with Propanolaminderivate, process for their production, medicaments containing these compounds and their use
04/13/2000DE19845285A1 Treatment or prophylaxis of feline infectious peritonitis, using glyoxal or derivative, preferably in combination with immunostimulant
04/13/2000DE19843968A1 Taxane enthaltende pharmazeutische Zubereitung zur intravenösen Applikation und Verfahren zu ihrer Herstellung Taxanes containing pharmaceutical preparation for intravenous administration and processes for their preparation
04/13/2000DE19842416A1 Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden Secondary amines for the prevention and treatment of diseases that are caused or aggravated by oxidation processes
04/13/2000CA2354863A1 Prevention of adhesions
04/13/2000CA2347120A1 Nlk1 -interacting proteins
04/13/2000CA2346865A1 Cytotoxic alkaloids (halitulin)
04/13/2000CA2346765A1 Compositions and methods of disease diagnosis and therapy
04/13/2000CA2346695A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
04/13/2000CA2346687A1 Use of rar antagonists or inverse agonists as male anit-fertility agents
04/13/2000CA2346665A1 Novel treatment for stroke management
04/13/2000CA2346646A1 Animal stereotypy
04/13/2000CA2346537A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof
04/13/2000CA2346463A1 Use of sodium salts of triazine anticoccidial agents for the prevention and treatment of protozoal disease
04/13/2000CA2346459A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
04/13/2000CA2346456A1 Method and compositions for increasing bone mass
04/13/2000CA2346452A1 Methods and adjuvants for stimulating mucosal immunity
04/13/2000CA2346445A1 Biphenylene lactams as prostaglandin receptor ligands
04/13/2000CA2346443A1 Prostaglandin receptor ligands
04/13/2000CA2346363A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
04/13/2000CA2346339A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
04/13/2000CA2346333A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
04/13/2000CA2346332A1 Oxybutynin formulations and methods of use
04/13/2000CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof
04/13/2000CA2346086A1 Composition for treatment of light-injured retinal degeneration disease
04/13/2000CA2346085A1 Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism
04/13/2000CA2346083A1 Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
04/13/2000CA2346053A1 Angiogenesis inhibitor
04/13/2000CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer
04/13/2000CA2346040A1 New bis-benzimidazoles
04/13/2000CA2346037A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
04/13/2000CA2346034A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
04/13/2000CA2346033A1 Imidazo[4,5-c-]-pyridin-4-one(sic) derivatives having factor xa-inhibiting action
04/13/2000CA2346029A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
04/13/2000CA2346019A1 Use of catechol derivatives as proteinase inhibitors
04/13/2000CA2345997A1 Benzamide derivatives as thrombin inhibitors
04/13/2000CA2345881A1 Bone marrow-derived serum proteins
04/13/2000CA2345808A1 Mucosal originated drug delivery systems and animal applications
04/13/2000CA2345789A1 New crystal modification iii of torasemide
04/13/2000CA2345729A1 Pharmaceutical compositions containing paclitaxel